Publication Name	World Journal of Gastroenterology
Manuscript ID	99374
Country	China

Received	2024-07-21 08:27
Peer-Review Started	2024-07-21 08:27
To Make the First Decision
Return for Revision	2024-08-05 21:08
Revised	2024-08-24 07:32
Second Decision	2024-09-06 03:03
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-09-06 05:58
Articles in Press	2024-09-06 05:58
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-09-12 17:00
Publish the Manuscript Online	2024-09-20 08:50

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Dual-targeted treatment for inflammatory bowel disease: Whether fecal microbiota transplantation can be an important part of it
Manuscript Source	Invited Manuscript
All Author List	Zi-Ning Zhang and Li-Xuan Sang
ORCID	Author(s) ORCID Number Li-Xuan Sang http://orcid.org/0000-0002-4562-0022
Funding Agency and Grant Number	Funding Agency Grant Number The Science and Technology Plan of Liaoning Province, China No. 2022JH2/101500063
Corresponding Author	Li-Xuan Sang, MD, PhD, Professor, Department of Gastroenterology, The Shengjing Hospital of China Medical University, No. 39 Gliding Road, Tiexi District, Shenyang 110022, Liaoning Province, China. sanglixuan2008@163.com
Key Words	Gut microbiota; Inflammatory bowel disease; Fecal microbiota transplantation; Dual-targeted treatment; Combination treatment
Core Tip	The combination of biologic agents or the combination of a biologic agent and a novel small-molecule drug for treating inflammatory bowel disease (IBD) carries certain risks, and some patients are resistant to these drugs. The regulation of the gut microbiota has become a potential treatment for IBD, and the inclusion of fecal bacteria transplantation in dual-targeted treatments for IBD holds great promise.
Publish Date	2024-09-20 08:50
Citation	<p>Zhang ZN, Sang LX. Dual-targeted treatment for inflammatory bowel disease: Whether fecal microbiota transplantation can be an important part of it. <i>World J Gastroenterol</i> 2024; 30(36): 4025-4030</p>
URL	https://www.wjgnet.com/1007-9327/full/v30/i36/4025.htm
DOI	https://dx.doi.org/10.3748/wjg.v30.i36.4025

Full Article (PDF)	WJG-30-4025-with-cover.pdf
Manuscript File	99374_Auto_Edited_014139.docx
Answering Reviewers	99374-answering-reviewers.pdf
Audio Core Tip	99374-audio.mp3
Conflict-of-Interest Disclosure Form	99374-conflict-of-interest-statement.pdf
Copyright License Agreement	99374-copyright-assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	99374-foundation-statement.pdf
Non-Native Speakers of English Editing Certificate	99374-non-native-speakers.pdf
Peer-review Report	99374-peer-reviews.pdf
Scientific Misconduct Check	99374-scientific-misconduct-check.png
Scientific Editor Work List	99374-scientific-editor-work-list.pdf
CrossCheck Report	99374-crosscheck-report.pdf